Auron Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aurontx.com
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Phase 1
Recruiting
- Conditions
- Relapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)Relapsed/Refractory AMLRelapsed Myelodysplastic SyndromesRefractory Myelodysplastic SyndromesRelapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Auron Therapeutics, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT06846606
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
© Copyright 2025. All Rights Reserved by MedPath